Jesse Shefferman News Today

Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company init...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Protara Therapeutics (TARA – Research Report), wit...

Protara Therapeutics (NASDAQ:TARA – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk. Insider & Institutional Ownership 50.3% of Protara Therapeutics shares […]

Protara Therapeutics (NASDAQ:TARA – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent ratings […]

Protara Therapeutics (NASDAQ:TARA – Get Rating) and Surrozen (NASDAQ:SRZN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current ratings and […]

GuruFocus Article or News written by Stock market mentor and the topic is about:

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer NEW YORK, January 10, 2022 - Protara Therapeutics, Inc. , a clinical-stage company... | January 10, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic ... Protara TherapeuticsApril 23, 2021 GMT NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TA...

Provided by GlobeNewswire Apr 23, 2021 11:00 AM UTC NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug...

Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors February 02, 2021 08:00 ET | Source: Protara Therapeutics Protara Therapeutics New York, New York, UNITED STATES NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment o...